000186571 001__ 186571
000186571 005__ 20240229154900.0
000186571 0247_ $$2doi$$a10.1158/1055-9965.EPI-22-0882
000186571 0247_ $$2pmid$$apmid:36595657
000186571 0247_ $$2ISSN$$a1055-9965
000186571 0247_ $$2ISSN$$a1538-7755
000186571 0247_ $$2altmetric$$aaltmetric:140835260
000186571 037__ $$aDKFZ-2023-00020
000186571 041__ $$aEnglish
000186571 082__ $$a610
000186571 1001_ $$00000-0001-6156-254X$$aLindley, Clara L$$b0
000186571 245__ $$aPre-surgery inflammatory and angiogenesis biomarkers as predictors of 12-month cancer-related distress: Results from the ColoCare Study.
000186571 260__ $$aPhiladelphia, Pa.$$bAACR$$c2023
000186571 3367_ $$2DRIVER$$aarticle
000186571 3367_ $$2DataCite$$aOutput Types/Journal article
000186571 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679472257_6243
000186571 3367_ $$2BibTeX$$aARTICLE
000186571 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186571 3367_ $$00$$2EndNote$$aJournal Article
000186571 520__ $$aColorectal cancer (CRC) patients commonly suffer from complex psychological distress. Elevated distress may be linked to systemic biomarkers. We investigated associations of biomarkers of inflammation and angiogenesis with cancer-related distress (CTXD) score.N=315 patients (stage I-IV) from 2 centers of the ColoCare Study were included: Huntsman Cancer Institute and University of Heidelberg. Biomarkers (e.g., IL-6, VEGF-A, VEGF-D) were measured in serum collected pre-surgery and 12 months thereafter. The CTXD overall score and 4 subscales were collected 12 months after surgery and dichotomized to investigate biomarkers as predictors of distress 12 months after surgery; adjusted for age, sex, body mass index, tumor stage, center, and baseline levels of biomarkers.Doubling of IL-6 predicted future increased risk of overall distress (Odds Ratio (OR) = 1.20; 95%Confidence Interval (CI) = 1.02-1.41; p = 0.03). VEGF-A predicted future increased risk of high family strain (VEGF-A: OR=1.21; 95%CI=1.01-1.44; p=0.04) and VEGF-D was associated with medical and financial demands (OR=1.34; 95%CI=1.01-1.74; p=0.03).This is the first study to show that systemic biomarkers are significantly associated with future CTXD score. Distress was not measured at baseline; we cannot rule out ongoing associations of inflammation and distress throughout treatment versus a direct effect of inflammation on distress. Nonetheless these data add to evidence that biobehavioral processes interact and that systemic biomarkers are associated with cancer-related distress one year after surgery.Exercise and diet interventions that lower systemic cytokine levels may impact longer term CTXD score and improve quality of life of CRC patients.
000186571 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186571 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186571 7001_ $$aGigic, Biljana$$b1
000186571 7001_ $$00000-0003-3645-3960$$aPeoples, Anita R$$b2
000186571 7001_ $$00000-0001-6081-3378$$aHan, Claire J$$b3
000186571 7001_ $$00000-0001-5147-8432$$aLin, Tengda$$b4
000186571 7001_ $$00000-0003-4084-8340$$aHimbert, Caroline$$b5
000186571 7001_ $$00000-0003-1772-8332$$aWarby, Christy A$$b6
000186571 7001_ $$00000-0001-8639-3543$$aBoehm, Juergen$$b7
000186571 7001_ $$00000-0003-0292-6168$$aHardikar, Sheetal$$b8
000186571 7001_ $$00000-0002-9676-7702$$aAshworth, Anjelica$$b9
000186571 7001_ $$aSchneider, Martin$$b10
000186571 7001_ $$00000-0003-1469-2186$$aUlrich, Alexis$$b11
000186571 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b12$$udkfz
000186571 7001_ $$00000-0001-8040-3341$$aFigueiredo, Jane C$$b13
000186571 7001_ $$00000-0003-1543-0743$$aLi, Christopher I$$b14
000186571 7001_ $$00000-0002-5670-423X$$aShibata, David$$b15
000186571 7001_ $$00000-0003-1779-2510$$aSiegel, Erin M$$b16
000186571 7001_ $$00000-0003-1079-2606$$aToriola, Adetunji T$$b17
000186571 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b18
000186571 7001_ $$00000-0001-8378-2797$$aSyrjala, Karen L$$b19
000186571 7001_ $$aOse, Jennifer$$b20
000186571 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-22-0882$$gp. EPI-22-0882$$n3$$p363–370$$tCancer epidemiology, biomarkers & prevention$$v32$$x1055-9965$$y2023
000186571 909CO $$ooai:inrepo02.dkfz.de:186571$$pVDB
000186571 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000186571 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186571 9141_ $$y2023
000186571 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-10
000186571 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-10
000186571 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-10
000186571 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2022$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000186571 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-19
000186571 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000186571 980__ $$ajournal
000186571 980__ $$aVDB
000186571 980__ $$aI:(DE-He78)C120-20160331
000186571 980__ $$aUNRESTRICTED